News Release

International Wex Technologies Inc. is proceeding with a Human Clinical Test of Tetrodin(HT)

Date: 1998/12/07

Human clinical testing of drug de-addiction using Tetrodin(HT) on 70 plus drug addicts will be taking place in the next two months. This clinical test will take place at the Nanning Addiction Treatment Hospital during December 1998 and January 1999. A number of doctors from several foreign countries have been invited to attend in order to gain first hand experience with the use of Tetrodin(HT). The list of the foreign doctors and visitors attending this test will be issued by IWT in early January 1999 when all are confirmed. These tests will be conducted using Good Clinical Practices (GCP) protocols and follow-up methods modeled after those used by China, Europe and North America for new drug approval organizations and the findings will be reported to international medical journals.

International Wex Technologies Inc. is developing the patented new product named Tetrodin(HT). Tetrodin(HT) is a non-narcotic pharmaceutical that has proven to be a safe and effective treatment for all opiate (heroin, opium, morphine, methadone, etc.) addictions. Tetrodin(HT) functions very well in both primary withdrawal treatment and abstinence maintenance (longer term use) of drug addiction.

For additional information on Tetrodin(HT), view the IWT website at http://www.wextech.ca or call Howard Milne at 604-683-8880 or 1-800-722-7549

Per: Donna Shum, Corporate Secretary